The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...

During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III ...

Waystar announced a new set of AI-powered tools designed to perform a variety of tasks, including appealing denied claims. 1 ...

The company revealed plans to increase the usage of AI in pharma at JP Morgan’s healthcare conference in San Francisco.

Amylyx Pharmaceuticals named Dan Monahan as its chief commercial officer. 1 According to a press release, he is assuming the role in time to oversee the commercialization of avexitide, a GLP-1 ...

San Francisco Police cancel time off requests to increase security at the J.P. Morgan Healthcare Conference after the recent murder of UnitedHealth Group CEO Brian Thompson. In the wake of the murder ...

Deloitte’s US life sciences sector leader discusses the trends he believes will have the most impact in 2025. According to a new report from Deloitte, the life sciences industry will have a ...

Blue Shield of California issued a statement regarding the devastating wildfires that have spread across large sections of the state. 1 While the combination of flames and winds continue to cause ...

In the race to bolster pipelines and drive growth, biopharma manufacturers are reexamining traditional practices and reimagining market research protocols. Biopharma business development and licensing ...

Swoop announced its acquisition of MyHealthTeam, creator of one of the largest opted-in patient social networks in the US. The companies share a vision of making vetted information more available for ...

‘Shape Shifting’ is a creator-led series that focuses on the scientific and cultural impact of GLP-1s. The two biggest stories in pharma in recent years have been the rise in popularity of GLP-1s and ...

John Hood, CEO, Endeavor BioMedicines discusses a potential timeline on availability of ENV-101 for patients with IPF and further validation of the treatment's safety profile. PE: Given the ...